Supernus Pharmaceuticals, Inc.
SUPN
Classement en actions
#5560
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
Prix de l'action
$41.01
Dernière synchronisation: 2026-10-21
Capitalisation boursière
$2.39B
Changement (1 jour)
-0.55%
Changement (1 an)
-18.33%
Pays
US
Échange Supernus Pharmaceuticals, Inc. (SUPN)
Catégorie
Healthcare
Historique du prix de l'action pour Supernus Pharmaceuticals, Inc. (SUPN)
Prix de clôture le plus élevé : $41.69 le 2026-10-01
Prix de clôture le plus bas : $40.92 le 2018-01-01
Prix de clôture le plus bas : $40.92 le 2018-01-01
Historique du prix de l'action de Supernus Pharmaceuticals, Inc. de 2018 à 2026
Performance annuelle du prix de l'action
| Année | Performance |
|---|---|
| 2026 (TTM) | -0.51% |
| 2025 | 31.56% |
| 2024 | 30.76% |
| 2023 | -22.16% |
| 2022 | 10.88% |
| 2021 | 36.92% |
| 2020 | -26.72% |
| 2019 | -18.72% |
| 2018 | 0.00% |
Prix de l'action pour des entreprises similaires ou concurrentes
| Entreprise | Prix de l'action | Variation 1a% | Pays |
|---|---|---|---|
| $171.67 | - |
DE
|
|
| $162.84 | 21.78% |
DE
|
|
| $40.45 | 43.11% |
JP
|
|
| $225.05 | 31.42% |
CH
|
|
| $18.43 | -4.03% |
IN
|
